 SAN DIEGO, Sept. 30, 2021 PRNewswire -- Regulus Therapeutics Inc. Nasdaq: RGLS, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs the Company or Regulus, today announced that David Baltimore, Ph.D. 